Fundamental Analysis of GENETIC TECH LTD-SP ADR(NASDAQ:GENE) stock

Fundamental Rating

We assign a fundamental rating of 1 out of 10 to GENE. GENE was compared to 58 industry peers in the Life Sciences Tools & Services industry. GENE may be in some trouble as it scores bad on both profitability and health. GENE has a expensive valuation and it also scores bad on growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year GENE has reported negative net income.

GENE had a negative operating cash flow in the past year.

GENE had negative earnings in each of the past 5 years.

In the past 5 years GENE always reported negative operating cash flow.

1.2 Ratios

With a Return On Assets value of -150.11%, GENE is not doing good in the industry: 98.28% of the companies in the same industry are doing better.

The Return On Equity of GENE (-264.12%) is worse than 91.38% of its industry peers.

		Industry Rank	Sector Rank
ROA	-150.11%
ROE	-264.12%
ROIC	N/A

ROA(3y)-48.06%

ROA(5y)-76.25%

ROE(3y)-60.51%

ROE(5y)-117.86%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

GENE has a Gross Margin of 53.55%. This is in the better half of the industry: GENE outperforms 62.07% of its industry peers.

The Profit Margin and Operating Margin are not available for GENE so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	53.55%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

GENE does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, GENE has more shares outstanding

GENE has less shares outstanding than it did 5 years ago.

Compared to 1 year ago, GENE has a worse debt to assets ratio.

2.2 Solvency

Based on the Altman-Z score of -26.21, we must say that GENE is in the distress zone and has some risk of bankruptcy.

Looking at the Altman-Z score, with a value of -26.21, GENE is doing worse than 94.83% of the companies in the same industry.

GENE has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.

The Debt to Equity ratio of GENE (0.02) is better than 68.97% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.02
Debt/FCF	N/A
Altman-Z	-26.21

ROIC/WACCN/A

WACC11.68%

2.3 Liquidity

GENE has a Current Ratio of 1.67. This is a normal value and indicates that GENE is financially healthy and should not expect problems in meeting its short term obligations.

GENE has a worse Current ratio (1.67) than 75.86% of its industry peers.

A Quick Ratio of 1.55 indicates that GENE should not have too much problems paying its short term obligations.

GENE's Quick ratio of 1.55 is on the low side compared to the rest of the industry. GENE is outperformed by 67.24% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	1.67
Quick Ratio	1.55

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for GENE have decreased strongly by -19.37% in the last year.

The Revenue has decreased by -4.57% in the past year.

Measured over the past years, GENE shows a very strong growth in Revenue. The Revenue has been growing by 114.96% on average per year.

EPS 1Y (TTM)-19.37%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q5.94%

Revenue 1Y (TTM)-4.57%

Revenue growth 3Y858.63%

Revenue growth 5Y114.96%

Revenue growth Q2Q-4.7%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

GENE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2YN/A

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

GENE does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

GENETIC TECH LTD-SP ADR

NASDAQ:GENE (5/2/2024, 5:17:54 PM)

After market: 2.29 +0.07 (+3.15%)

2.22

-0.14 (-5.93%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryLife Sciences Tools & Services

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap8.54M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-150.11%
ROE	-264.12%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	53.55%
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover1

Health

		Industry Rank	Sector Rank
Debt/Equity	0.02
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	1.67
Quick Ratio	1.55
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)-19.37%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next YN/A

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)-4.57%

Revenue growth 3Y858.63%

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

GENETIC TECH LTD-SP ADR (GENE)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens